Leap Therapeutics Inc (LPTX) — Cash Flow-to-Debt Ratio
Leap Therapeutics Inc (LPTX) has a Cash Flow-to-Debt Ratio of -1.87x as of September 2025, meaning its operating cash flow of $-16.29 Million could theoretically repay -2% of its total liabilities ($8.70 Million) in one year. See Leap Therapeutics Inc (LPTX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Leap Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Leap Therapeutics Inc across 13 annual periods. Also explore Leap Therapeutics Inc (LPTX) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Leap Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Leap Therapeutics Inc. For market capitalisation and broader financial context, see Leap Therapeutics Inc (LPTX) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.28x | $-60.30 Million | $14.08 Million | ▼ -24.2% |
| 2023 | -3.45x | $-43.75 Million | $12.68 Million | ▲ +75.7% |
| 2022 | -14.22x | $-49.04 Million | $3.45 Million | ▼ -305.4% |
| 2021 | -3.51x | $-35.16 Million | $10.02 Million | ▲ +59.3% |
| 2020 | -8.62x | $-25.96 Million | $3.01 Million | ▼ -194.8% |
| 2019 | -2.93x | $-26.90 Million | $9.20 Million | ▼ -11.2% |
| 2018 | -2.63x | $-26.03 Million | $9.90 Million | ▼ -113.2% |
| 2017 | -1.23x | $-22.14 Million | $17.95 Million | ▲ +68.6% |
| 2016 | -3.92x | $-25.34 Million | $6.46 Million | ▲ +74.4% |
| 2015 | -15.31x | $-19.58 Million | $1.28 Million | ▼ -111.4% |
| 2014 | -7.24x | $-18.02 Million | $2.49 Million | ▼ -43.6% |
| 2013 | -5.04x | $-9.94 Million | $1.97 Million | ▼ -208.1% |
| 2012 | -1.64x | $-7.55 Million | $4.61 Million | — |